Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma. [electronic resource]
Producer: 20030926Description: 130-8 p. digitalISSN:- 1524-9557
- Aged
- Carcinoma, Renal Cell -- immunology
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Granulocyte-Macrophage Colony-Stimulating Factor -- administration & dosage
- Humans
- Immunotherapy -- methods
- Injections, Intravenous
- Injections, Subcutaneous
- Interleukin-2 -- administration & dosage
- Kidney Neoplasms -- immunology
- Male
- Maximum Tolerated Dose
- Melanoma -- immunology
- Middle Aged
- Neoplasm Metastasis
- Reference Values
- Risk Assessment
- Skin Neoplasms -- immunology
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.